UA91007C2 - Замещенные 6-циклогексилалкилом замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли-(адф-рибоза)полимеразы - Google Patents
Замещенные 6-циклогексилалкилом замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли-(адф-рибоза)полимеразыInfo
- Publication number
- UA91007C2 UA91007C2 UAA200605781A UAA200605781A UA91007C2 UA 91007 C2 UA91007 C2 UA 91007C2 UA A200605781 A UAA200605781 A UA A200605781A UA A200605781 A UAA200605781 A UA A200605781A UA 91007 C2 UA91007 C2 UA 91007C2
- Authority
- UA
- Ukraine
- Prior art keywords
- substituted
- quinoxalinones
- quinolinones
- adp
- ribose
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03078918 | 2003-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA91007C2 true UA91007C2 (ru) | 2010-06-25 |
Family
ID=34684557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200605781A UA91007C2 (ru) | 2003-12-10 | 2004-11-18 | Замещенные 6-циклогексилалкилом замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли-(адф-рибоза)полимеразы |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7652014B2 (ru) |
| EP (1) | EP1694653B1 (ru) |
| JP (1) | JP4948178B2 (ru) |
| KR (1) | KR101149031B1 (ru) |
| CN (2) | CN1890225A (ru) |
| AU (1) | AU2004299183B2 (ru) |
| BR (1) | BRPI0417571A (ru) |
| CA (1) | CA2548273C (ru) |
| EA (1) | EA010592B1 (ru) |
| ES (1) | ES2565581T3 (ru) |
| IL (1) | IL176199A (ru) |
| NO (1) | NO337621B1 (ru) |
| NZ (1) | NZ547278A (ru) |
| SG (1) | SG151250A1 (ru) |
| UA (1) | UA91007C2 (ru) |
| WO (1) | WO2005058843A1 (ru) |
| ZA (1) | ZA200604774B (ru) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG150534A1 (en) | 2003-11-20 | 2009-03-30 | Janssen Pharmaceutica Nv | 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp- ribose) polymerase inhibitors |
| SG150533A1 (en) | 2003-11-20 | 2009-03-30 | Janssen Pharmaceutica Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| US7902225B2 (en) * | 2004-01-23 | 2011-03-08 | Janssen Pharmaceutica Nv | Mycobacterial inhibitors |
| EA011552B1 (ru) | 2004-06-30 | 2009-04-28 | Янссен Фармацевтика Н.В. | Производные хиназолиндиона в качестве ингибиторов parp |
| KR101211950B1 (ko) | 2004-06-30 | 2012-12-13 | 얀센 파마슈티카 엔.브이. | Ｐａｒｐ 저해제로서의 프탈아진 유도체 |
| UA85593C2 (ru) | 2004-06-30 | 2009-02-10 | Янссен Фармацевтика Н.В. | Производные хиназолинона как ингибиторы parp |
| WO2007011962A2 (en) | 2005-07-18 | 2007-01-25 | Bipar Sciences, Inc. | Treatment of cancer |
| CA2662517A1 (en) | 2006-09-05 | 2008-03-13 | Jerome Moore | Treatment of cancer |
| CN102379884A (zh) | 2006-09-05 | 2012-03-21 | 彼帕科学公司 | Parp抑制剂对脂肪酸合成的抑制及其治疗方法 |
| ATE542799T1 (de) * | 2007-03-08 | 2012-02-15 | Janssen Pharmaceutica Nv | Chinolinonderivate als parp und tank-inhibitoren |
| PL2215075T3 (pl) * | 2007-10-26 | 2014-04-30 | Janssen Pharmaceutica Nv | Pochodne chinolinonu jako inhibitory PARP |
| MX2010005222A (es) | 2007-11-12 | 2010-09-28 | Bipar Sciences Inc | Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales. |
| WO2009118382A1 (en) | 2008-03-27 | 2009-10-01 | Janssen Pharmaceutica Nv | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors |
| WO2009118384A1 (en) | 2008-03-27 | 2009-10-01 | Janssen Pharmaceutica Nv | Quinazolinone derivatives as tubulin polymerization inhibitors |
| CA2750106A1 (en) | 2009-01-23 | 2010-07-29 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| EP2459561A1 (en) | 2009-07-30 | 2012-06-06 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| BR112015008515A2 (pt) | 2012-10-16 | 2017-07-04 | Janssen Pharmaceutica Nv | moduladores de ror t de quinolinila ligada à heteroarila |
| CN105073729A (zh) | 2012-10-16 | 2015-11-18 | 詹森药业有限公司 | RORγt的苯基连接的喹啉基调节剂 |
| AR093017A1 (es) | 2012-10-16 | 2015-05-13 | Janssen Pharmaceutica Nv | MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| BR112016008215A2 (pt) | 2013-10-15 | 2017-09-26 | Janssen Pharmaceutica Nv | moduladores de quinolinila ligados por alquila de roryt |
| CA2927182A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | Quinolinyl modulators of ror.gamma.t |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| CA2977685C (en) | 2015-03-02 | 2024-02-20 | Sinai Health System | Homologous recombination factors |
| CN108138177B9 (zh) | 2015-07-23 | 2021-08-13 | 法国居里学院 | Dbait分子与PARP抑制剂的组合用于治疗癌症的用途 |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| CN106588993A (zh) * | 2016-09-02 | 2017-04-26 | 瑞声光电科技(常州)有限公司 | 铱配合物及其制备方法和应用该铱配合物的发光器件 |
| BR112019006448A2 (pt) | 2016-09-29 | 2019-06-25 | Bayer Cropscience Ag | novos derivados de 5-imidazol substituídos |
| KR20190107656A (ko) | 2016-11-02 | 2019-09-20 | 이뮤노젠 아이엔씨 | 항체-약물 콘주게이트 및 parp 억제제로 병용 치료 |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| WO2018197461A1 (en) | 2017-04-28 | 2018-11-01 | Akribes Biomedical Gmbh | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
| US20200407720A1 (en) | 2018-03-13 | 2020-12-31 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| CN114144413A (zh) | 2019-07-19 | 2022-03-04 | 阿斯利康(瑞典)有限公司 | Parp1抑制剂 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI77852C (fi) * | 1981-02-17 | 1989-05-10 | Otsuka Pharma Co Ltd | Foerfarande foer framstaellning av nya, saosom hjaertmediciner anvaendbara substituerade amid- och (maettad heterocykel)karbonylkarbostyrilderivat. |
| AU532361B2 (en) * | 1981-09-01 | 1983-09-29 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| KR0149162B1 (ko) * | 1988-11-29 | 1998-10-15 | 구스타프 반 리이트 | (1h-아졸-1-일메틸) 치환된 퀴놀린, 퀴나졸린 또는 퀴녹살린 유도체 |
| CA2002864C (en) | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
| US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| AU9384701A (en) * | 2000-10-02 | 2002-04-15 | Janssen Pharmaceutica Nv | Metabotropic glutamate receptor antagonists |
| MXPA04009435A (es) * | 2002-03-29 | 2005-01-25 | Janssen Pharmaceutica Nv | Derivados de quinolina y quinolinona radiomarcados y su uso como ligandos de receptor de glutamato metabotropico. |
| AU2004295059B2 (en) * | 2003-12-05 | 2010-12-16 | Janssen Pharmaceutica N.V. | 6-substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
-
2004
- 2004-11-18 WO PCT/EP2004/013165 patent/WO2005058843A1/en active Application Filing
- 2004-11-18 UA UAA200605781A patent/UA91007C2/ru unknown
- 2004-11-18 CN CNA2004800366563A patent/CN1890225A/zh active Pending
- 2004-11-18 JP JP2006543409A patent/JP4948178B2/ja not_active Expired - Fee Related
- 2004-11-18 KR KR1020067013344A patent/KR101149031B1/ko not_active IP Right Cessation
- 2004-11-18 BR BRPI0417571-9A patent/BRPI0417571A/pt not_active Application Discontinuation
- 2004-11-18 ES ES04803192.6T patent/ES2565581T3/es active Active
- 2004-11-18 NZ NZ547278A patent/NZ547278A/en not_active IP Right Cessation
- 2004-11-18 AU AU2004299183A patent/AU2004299183B2/en not_active Ceased
- 2004-11-18 EP EP04803192.6A patent/EP1694653B1/en active Active
- 2004-11-18 SG SG200901548-8A patent/SG151250A1/en unknown
- 2004-11-18 EA EA200601125A patent/EA010592B1/ru not_active IP Right Cessation
- 2004-11-18 CN CN201110081918XA patent/CN102206180B/zh not_active Expired - Fee Related
- 2004-11-18 CA CA2548273A patent/CA2548273C/en not_active Expired - Fee Related
- 2004-11-18 US US10/596,083 patent/US7652014B2/en not_active Expired - Fee Related
-
2006
- 2006-06-08 IL IL176199A patent/IL176199A/en not_active IP Right Cessation
- 2006-06-09 ZA ZA200604774A patent/ZA200604774B/xx unknown
- 2006-07-05 NO NO20063129A patent/NO337621B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102206180A (zh) | 2011-10-05 |
| CN102206180B (zh) | 2013-05-29 |
| JP4948178B2 (ja) | 2012-06-06 |
| CA2548273A1 (en) | 2005-06-30 |
| EA010592B1 (ru) | 2008-10-30 |
| KR101149031B1 (ko) | 2012-05-29 |
| CA2548273C (en) | 2013-04-16 |
| EP1694653A1 (en) | 2006-08-30 |
| WO2005058843A8 (en) | 2006-06-15 |
| US20090042881A1 (en) | 2009-02-12 |
| CN1890225A (zh) | 2007-01-03 |
| KR20060108753A (ko) | 2006-10-18 |
| NZ547278A (en) | 2010-01-29 |
| EA200601125A1 (ru) | 2006-10-27 |
| SG151250A1 (en) | 2009-04-30 |
| ZA200604774B (en) | 2007-11-28 |
| IL176199A (en) | 2012-03-29 |
| US7652014B2 (en) | 2010-01-26 |
| AU2004299183B2 (en) | 2010-09-23 |
| WO2005058843A1 (en) | 2005-06-30 |
| ES2565581T3 (es) | 2016-04-05 |
| JP2007513898A (ja) | 2007-05-31 |
| BRPI0417571A (pt) | 2007-03-20 |
| NO337621B1 (no) | 2016-05-09 |
| NO20063129L (no) | 2006-07-05 |
| IL176199A0 (en) | 2006-10-05 |
| AU2004299183A1 (en) | 2005-06-30 |
| EP1694653B1 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA91007C2 (ru) | Замещенные 6-циклогексилалкилом замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли-(адф-рибоза)полимеразы | |
| UA89618C2 (ru) | 6-замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы | |
| UA91002C2 (ru) | 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы | |
| TW200610531A (en) | Phthalazine derivatives as PARP inhibitors | |
| SG154432A1 (en) | Quinazolinedione derivatives as parp inhibitors | |
| SG154434A1 (en) | Quinazolinone derivatives as parp inhibitors | |
| WO2004074244A3 (en) | Pyrimidine compounds | |
| ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
| UA91027C2 (ru) | ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЯ МЕЖДУ MDM2 И р53 | |
| SE0101675D0 (sv) | Novel composition | |
| WO2003095455A3 (en) | Substituted pyrazolopyrimidines | |
| WO2004080377A3 (en) | Kcnq channel modulating compounds and their pharmaceutical use | |
| WO2004106293A3 (en) | Oxazolyl - and thiazolyl - purine based tricyclic compounds. | |
| SE0302139D0 (sv) | Novel compounds | |
| TW200604197A (en) | New compounds | |
| WO2004075846A3 (en) | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | |
| WO2005011609A3 (en) | Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | |
| SE0303280D0 (sv) | Novel compounds | |
| DE60201074D1 (en) | Pyrazolopyridinderivate | |
| SE0302755D0 (sv) | Novel compounds | |
| MY154363A (en) | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors | |
| UA86777C2 (en) | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors | |
| BR0210099A (pt) | Agentes antibacterianos |